If You Invested in Crescent Biopharma, Inc. (CBIO)
Looking for the current price? See the CBIO quote & overviewWhat $1,000 or $10,000 in CBIO Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Oct 30, 2015 |
|---|---|---|---|---|
| $1,000 | $1,080 +8% | $274 -73% | $83 -92% | $16 -98% |
| $10,000 | $10,800 +8% | $2,736 -73% | $833 -92% | $155 -98% |
Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-10-28. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for CBIO$1,000 Investment Over Time
CBIO vs S&P 500Year-by-Year Returns
CBIO annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2015 | $868.50 | $704.25 | -18.9% | -18.9% |
| 2016 | $704.25 | $146.25 | -79.2% | -83.2% |
| 2017 | $146.25 | $204.60 | +39.9% | -76.4% |
| 2018 | $204.60 | $118.35 | -42.2% | -86.4% |
| 2019 | $118.35 | $102.15 | -13.7% | -88.2% |
| 2020 | $102.15 | $94.65 | -7.3% | -89.1% |
| 2021 | $94.65 | $13.71 | -85.5% | -98.4% |
| 2022 | $13.71 | $7.91 | -42.3% | -99.1% |
| 2023 | $7.91 | $7.67 | -3.1% | -99.1% |
| 2025 | $7.67 | $11.86 | +54.6% | -98.6% |
| 2026 | $11.86 | $13.50 | +13.8% | -98.4% |
About Crescent Biopharma, Inc.
Healthcare · NASDAQ
Crescent Biopharma, Inc. (Nasdaq: CBIO) is a clinical-stage biotechnology company developing oncology therapeutics for solid tumors. The company’s pipeline is built around antibody-based drug candidates, led by CR-001, a PD-1 x VEGF bispecific antibody, and includes antibody-drug conjugate programs such as CR-002 and CR-003.
Crescent focuses on multiple therapeutic modalities and established oncology targets. Its development strategy includes evaluating drug candidates as single agents and as part of combination regimens for a range of solid tumor settings. The company has described CR-001 as its lead program and as a potential immuno-oncology backbone candidate, while its ADC programs extend the pipeline into targeted drug-delivery approaches.
Pipeline and development focus
The company’s lead clinical program, CR-001, is a bispecific antibody designed to engage both PD-1 and VEGF pathways. Crescent has described the ASCEND study as a Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types. The company’s pipeline also includes ADC programs directed at validated oncology targets, including CR-002, identified as a PD-L1-targeted ADC, and CR-003, identified as an ITGB6-targeted ADC.
Crescent has reported a partnership with Kelun-Biotech that expands its pipeline and supports combination development involving CR-001 and antibody-drug conjugates. The company’s oncology work is centered on solid tumors and on therapeutic approaches that combine immuno-oncology and targeted cytotoxic payload delivery.
Corporate profile
Crescent Biopharma’s ordinary shares trade on Nasdaq under the symbol CBIO. The company is incorporated in the Cayman Islands and maintains principal offices in Waltham, Massachusetts. As a clinical-stage biotechnology issuer, Crescent’s public-company disclosures primarily center on research and development activity, clinical programs, financing, equity compensation, governance, and capital structure rather than commercial product revenue.
Similar Stocks
See how related companies performed
Frequently Asked Questions
Crescent Biopharma, Inc. investment returns
How much would $1,000 invested in Crescent Biopharma, Inc. be worth today?
If you invested $1,000 in Crescent Biopharma, Inc. (CBIO) 10 years ago on 2016-10-31, your investment would be worth $83 as of 2026-10-28, a -91.7% price return without dividends, growing at a compounded rate of -22.0% per year (CAGR).
Has Crescent Biopharma, Inc. outperformed the S&P 500?
Over the past 10 years, CBIO returned -91.7% compared to +263.4% for the S&P 500, underperforming the benchmark by 355.0 percentage points.
What is Crescent Biopharma, Inc.'s average annual return?
The compound annual growth rate (CAGR) of CBIO’s share price over the past 10 years is -22.0%, without dividends. Individual years vary a great deal, and CBIO’s best recent full year was 2017 (+39.9%) while the worst was 2021 (-85.5%).
For informational and educational purposes only, not investment advice.
